Sadashiva Pai: How Pancreatic Cancer Uses Blood Clotting to Evade Immune Attack
Sadashiva Pai, Editorial Board at Aging Brain, Founder and CEO of Science Mission LLC, shared a post on LinkedIn:
“Pancreatic cancer uses blood-clotting system to evade immune attack
Pancreatic ductal adenocarcinoma is among the deadliest cancers, with a five-year survival rate of about 13 percent. While immunotherapies have transformed treatment for several cancers, they have shown little success against pancreatic cancer because the tumor environment can prevent immune cells from recognizing and attacking cancer cells.
The investigators identified two proteins produced by pancreatic cancer cells, PAI1 and PAI2, as key drivers of immune protection.
These proteins promote the buildup of fibrin, a protein normally involved in blood clotting and wound healing. The fibrin-rich environment attracts, educates, and retains macrophages, which can prevent cancer-fighting immune cells, including T cells, from reaching the tumor.
The findings shed light on how pancreatic cancer can resist immunotherapy and may also help explain why patients with pancreatic cancer are more susceptible to blood-clotting complications such as deep vein thrombosis. The findings suggest that tumors can increase blood clotting while suppressing immune activity.
One of the study’s most surprising findings was that these protective niches can be created by only a small fraction of tumor cells. In laboratory models, even when just 5 percent of implanted pancreatic cancer cells produced PAI1, they were able to reshape the surrounding immune environment, increasing immune-suppressing macrophages while reducing the number of activated T cells nearby.
The researchers also explored whether these immune-protective niches could be disrupted.
In multiple preclinical models, removing the genes responsible for producing PAI1 or PAI2, or blocking the pathway with an experimental drug, reduced immune suppression, slowed tumor growth, and significantly improved the effectiveness of anti-PD-1 immunotherapy.
Blocking interactions between fibrin and macrophages produced similar results.
Although additional research will be needed before these findings can be translated into treatments for patients, the study identifies several potential therapeutic targets that could eventually be combined with existing immunotherapies to improve outcomes for people with pancreatic cancer.”
Stay updated with Hemostasis Today.
-
Sep 30, 2026, 22:28Recent Mechanical Risk Factors and Young-Onset Cryptogenic Ischemic Stroke – American Heart Association International
-
Sep 30, 2026, 22:22Expert Consensus on Inferior Vena Cava Thrombosis – Thrombosis and Haemostasis Journal
-
Sep 30, 2026, 22:21Markus Abeln: How Platelets, Coagulation, Glycosylation, and Complement Regulate Placental Blood Flow
-
Sep 30, 2026, 22:19Fatma Al Arbawi: Studying Blood Clot Mechanics to Understand Aspirin Resistance and Thrombosis
-
Sep 30, 2026, 22:17Sudhir Kumar: Stroke is a Medical Emergency – and Every Minute Matters
-
Sep 30, 2026, 22:15Luisa Medeiros Visentini: Our Research on Cognitive Impairment After CVT Cited in the International Journal of Stroke
-
Sep 30, 2026, 21:50Jagat Narula: Connecting Cardiovascular Health and Sickle Cell Disease on World Heart Day 2026
-
Sep 30, 2026, 21:38John Kastelein: Exploring the Biology of Cardiovascular Disease at BioCentury Grand Rounds Europe
-
Sep 30, 2026, 21:36Mark Murphy: Irish Heart Foundation Meets With Senator Teresa Costello on World Heart Day